---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-027863"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2023-10-06T23:59:59+00:00"
generated_at: "2026-06-10T03:30:31.862723+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech shareholders approve reverse stock split authorization at special meeting

## Summary
- Reverse split proposal approved: 9,796,443 For, 6,858,043 Against, 170,202 Abstain.
- Board authorized to choose ratio between 1-for-5 and 1-for-20 within one year.
- Adjournment proposal also approved: 10,036,330 For, 6,686,830 Against, 101,528 Abstain.
- Board has not yet decided whether to implement a reverse split as of filing date.

## SEC filing metadata
- accession: 0001437749-23-027863
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2023-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774923027863/0001437749-23-027863-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774923027863/mbrx20231003_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-027863
- JSON: https://secwatch.observer/filing/0001437749-23-027863.json
- Plain text: https://secwatch.observer/filing/0001437749-23-027863.txt

## Key facts
- Shareholder Votes
  Moleculin Biotech, Inc. shareholders approved Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Split Proposal at the 2023-10-03 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-10-03
  source text: Proposal 2. Approve an Adjournment - The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Split Proposal (the “Adjournment Proposal”), by the following vote: Votes For Votes Against Abstain 10,036,330 6,686,830 101,528
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774923027863/0001437749-23-027863-index.htm
- Shareholder Votes
  Moleculin Biotech, Inc. shareholders approved To Effect a Reverse Stock Split of the Outstanding Shares - The Company's stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to grant the Board of Directors authority to effect a reverse stock split of the outstanding shares of the Company’s common at the 2023-10-03 meeting.
  - Proposal: reverse split
  - Outcome: passed
  - Meeting: 2023-10-03
  source text: Proposal 1. To Effect a Reverse Stock Split of the Outstanding Shares - The Company's stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to grant the Board of Directors authority to effect a reverse stock split of the outstanding shares of the Company’s common stock, at a reverse stock split ratio of between 1-for-5 and 1-for-20 as determined by the Board in its sole discretion, prior to the one-year anniversary of this Special Meeting (the “Reverse Split Proposal”), by the following vote: Votes For Votes Against Abstain 9,796,443 6,858,043 170,202
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774923027863/0001437749-23-027863-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.